New drug combo aims to outsmart tough colorectal cancer

NCT ID NCT06634875

Recruiting now Disease control Sponsor: Buzzard Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a new drug called isunakinra to the immunotherapy pembrolizumab can help treat advanced colorectal cancer that has not responded to other treatments. The trial will enroll 20 people with a specific type of tumor (MSS, TMB-H, KRAS-mutated). Researchers will check safety and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isunakinra (a drug that blocks IL-1) combined with pembrolizumab (an immunotherapy)
What this could lead to: If it works, this could offer a new treatment option for people with advanced colorectal cancer that has not responded to standard therapies.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER METASTATIC

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Hoag Memorial Hospital Presbyterian
RECRUITING

Newport Beach, California, 92658, United States
USC/Norris Cancer Center
RECRUITING

Los Angeles, California, 90089, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.